1530 Stock Overview
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1530 from our risk checks.
3SBio Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$5.97 |
52 Week High | HK$8.39 |
52 Week Low | HK$4.91 |
Beta | 0.75 |
1 Month Change | 10.97% |
3 Month Change | -10.23% |
1 Year Change | -26.21% |
3 Year Change | -13.48% |
5 Year Change | -61.08% |
Change since IPO | -39.33% |
Recent News & Updates
Recent updates
Shareholder Returns
1530 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 10.6% | -5.5% | -1.2% |
1Y | -26.2% | -43.0% | -12.2% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned -42.8% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned -13.4% over the past year.
Price Volatility
1530 volatility | |
---|---|
1530 Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1530's share price has been volatile over the past 3 months.
Volatility Over Time: 1530's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 5,311 | Jing Lou | https://www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation.
3SBio Inc. Fundamentals Summary
1530 fundamental statistics | |
---|---|
Market cap | HK$14.32b |
Earnings (TTM) | HK$2.09b |
Revenue (TTM) | HK$8.19b |
6.8x
P/E Ratio1.7x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1530 income statement (TTM) | |
---|---|
Revenue | CN¥7.55b |
Cost of Revenue | CN¥1.24b |
Gross Profit | CN¥6.31b |
Other Expenses | CN¥4.38b |
Earnings | CN¥1.93b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.80 |
Gross Margin | 83.57% |
Net Profit Margin | 25.55% |
Debt/Equity Ratio | 30.9% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield11%
Payout RatioDoes 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks3SBio dividend dates | |
---|---|
Ex Dividend Date | Jul 22 2024 |
Dividend Pay Date | Aug 05 2024 |
Days until Ex dividend | 118 days |
Days until Dividend pay date | 132 days |
Does 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks